Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13766923 | 0.97 | EPHX2 (0.51) | EPHX2HSD11B1HTTLMNACNR1 | |
| SCHEMBL12576479 | 0.95 | EPHX2 (0.52) | EPHX2HSD11B1HTTLMNACNR1 | |
| SCHEMBL13766959 | 0.91 | HSD11B1 (0.50) | EPHX2HSD11B1HTTLMNA | |
| SCHEMBL13766700 | 0.89 | HSD11B1 (0.53) | EPHX2HSD11B1HTTLMNACNR1 | |
| SCHEMBL13766926 | 0.87 | HSD11B1 (0.48) | EPHX2HSD11B1HTTLMNACNR2 | |
| SCHEMBL13767007 | 0.84 | HSD11B1 (0.60) | HSD11B1HTTLMNACNR1CNR2 | |
| SCHEMBL13766965 | 0.82 | HSD11B1 (0.48) | EPHX2HSD11B1HTTLMNA | |
| SCHEMBL13766928 | 0.81 | HSD11B1 (0.46) | EPHX2HSD11B1HTTLMNACNR2 | |
| SCHEMBL20108738 | 0.81 | CNR1 (0.40) | EPHX2HSD11B1LMNACNR1CNR2 | |
| SCHEMBL17226699 | 0.81 | HSD11B1 (0.42) | EPHX2HSD11B1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324265-B2 | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8324265-B2 | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD17B1, HSD11B1, HSD3B1 | EPHX2 865/4885HSD11B1 2/4885HTT 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.